TY - JOUR
T1 - Effectiveness of Vaccines and Monoclonal Antibodies Against Respiratory Syncytial Virus
T2 - Generic Protocol for Register-Based Cohort Study
AU - PROMISE Investigators
AU - Poukka, Eero
AU - Roekel, Caren van
AU - Turunen, Topi
AU - Baum, Ulrike
AU - Kramer, Rolf
AU - Begier, Elizabeth
AU - Presser, Lance
AU - Teirlinck, Anne
AU - Heikkinen, Terho
AU - Knol, Mirjam
AU - Nohynek, Hanna
AU - Nair, Harish
AU - Campbell, Harry
AU - Bont, Louis
AU - Perl, Leor
AU - Meijer, Adam
AU - Teirlinck, Anne C.
AU - Soudry, Shiri
AU - Gideonse, David
AU - Backx, Anoek
AU - Melker, Hester de
AU - Presser, Lance D.
AU - Cohen, Rachel
AU - Wang, Xin
AU - Saukkoriipi, Annika
AU - Paget, John
AU - Summeren, Jojanneke van
AU - Dückers, Michel
AU - Sperling, Daniel
AU - Audenis, Berta Gumí
AU - Llavero, Maica
AU - Kragten, Leyla
AU - Kriek, Lies
AU - Faksová, Kristýna
AU - Giardini, Michele
AU - Emborg, Hanne Dorthe
AU - Rocchi, Francesca
AU - Quiles, Cintia Muñoz
AU - Diez-Domingo, Javier
AU - Vernhes, Charlotte
AU - Demont, Clarisse
AU - Robin, Aurelie
AU - Neveu, David
AU - Marcelon, Lydie
AU - Bangert, Mathieu
AU - Daghash, Jamal
AU - Martyn, Oliver
AU - Bardone, Corinne
AU - Remy, Vanessa
AU - Chaves, Sandra
N1 - Publisher Copyright:
© 2024 Oxford University Press. All rights reserved.
PY - 2024/3/15
Y1 - 2024/3/15
N2 - Several immunization products are currently being developed against respiratory syncytial virus (RSV) for children, pregnant females, and older adults, and some products have already received authorization. Therefore, studies to monitor the effectiveness of these products are needed in the following years. To assist researchers to conduct postmarketing studies, we developed a generic protocol for register-based cohort studies to evaluate immunization product effectiveness against RSV-specific and nonspecific outcomes. To conduct a study on the basis of this generic protocol, the researchers can use any relevant databases or healthcare registers that are available at the study site.
AB - Several immunization products are currently being developed against respiratory syncytial virus (RSV) for children, pregnant females, and older adults, and some products have already received authorization. Therefore, studies to monitor the effectiveness of these products are needed in the following years. To assist researchers to conduct postmarketing studies, we developed a generic protocol for register-based cohort studies to evaluate immunization product effectiveness against RSV-specific and nonspecific outcomes. To conduct a study on the basis of this generic protocol, the researchers can use any relevant databases or healthcare registers that are available at the study site.
KW - RSV
KW - maternal immunization
KW - monoclonal antibody
KW - respiratory syncytial virus
KW - vaccine
UR - https://www.scopus.com/pages/publications/85186564817
U2 - 10.1093/infdis/jiad484
DO - 10.1093/infdis/jiad484
M3 - Article
C2 - 37930815
AN - SCOPUS:85186564817
SN - 1537-6613
VL - 229
SP - S84-S91
JO - The Journal of infectious diseases
JF - The Journal of infectious diseases
ER -